As a GLP-1 and GIP receptor agonist, Zepbound helps patients reduce their appetite, aiding in weight loss by decreasing food intake
Compared to the placebo group, those who received the silymarin saw a "significant decrease" in their levels of key diabetic markers hemoglobin A1C, fasting blood sugar, total cholesterol, low-density lipoprotein ("bad") cholesterol, and triglycerides.17 The second is a recent review published in the Annals of Hepatology in 2021, much of which relates to silymarin's effect on insulin resistance,18 a prominent marker for type 2 diabetes.19 Two of the studies referenced in the review were animal studies that administered 26.25-100mg/kg of silybin to rat subjects (equivalent to around 366-1,395mg for an 86kg, or 190lb, human) across 6-12 weeks
Zepbound has shown average weight loss of more than 20% in late-stage studies
Push on syringe plunger to release 2 to 3 drops of B12, ensuring that there is no more air in the barrel
